Enhertu

Enhertu (Trastuzumab Deruxtecan) is an advanced intravenous medication used for targeted cancer therapy. This innovative treatment combines a monoclonal antibody with a cytotoxic agent to deliver precise therapy.

Enhertu is primarily used in the treatment of certain types of cancer, particularly those that overexpress the HER2 protein. This medication is designed to target and destroy cancer cells while minimizing damage to healthy tissues. Patients often wonder, 'What is Enhertu used for?' It is typically prescribed for advanced or metastatic cancers that have progressed despite other treatments.

Common effects of Enhertu may include fatigue, nausea, and hair loss. Some patients may experience more severe side effects, such as decreased blood cell counts or damage to the lungs. It is important to discuss any unusual symptoms with a healthcare provider.

Enhertu should be handled with care and administered by healthcare professionals. Patients should be monitored regularly for signs of adverse reactions. Pregnant women or those planning to become pregnant should consult their healthcare provider before starting this medication.

Enhertu may interact with other medications, including those that suppress the immune system or affect blood cell production. Patients should inform their healthcare provider about all medications they are taking to avoid potential interactions.